Preview

Modern Rheumatology Journal

Advanced search

Evaluation of the efficacy and safety of a combination of chondroitin sulfate and glucosamine sulfate for knee and hip osteoarthritis in real clinical practice

https://doi.org/10.14412/1996-7012-2020-4-82-90

Abstract

A combination of chondroitin and glucosamine is widely used in clinical practice as both a symptomatic and structure-modifying agent for the treatment of osteoarthritis (OA). The emergence of new drugs based on this combination substantially expands treatment options for OA therapy.

Objective: to evaluate the efficacy and safety of Artroflex® that is a combination of chondroitin sulfate 400 mg and glucosamine sulfate 500 mg (CS + GS) to support joint health in patients with knee and/or hip OA.

Patients and methods. When implementing an open observational research program, the results of using the CS + GS complex were assessed in 644 OA patients (74.7% women) (mean age, 58.0±14.6 years) who experienced moderate/severe pain and required to continuously take non-steroidal anti-inflammatory drugs (NSAIDs). The CS + GS complex was prescribed in a dose of 2 capsules per day for 3 months. The investigators estimated changes in pain on movement by a 0 to 10 verbal pain scale, general health (GH) by a 0–10 visual analogue scale), the Lequesne index, the need for NSAIDs, and patient satisfaction with treatment and its tolerance.

Results and discussion. After 3-month therapy, there were decreases in pain intensity by 49.2±16.8%, GH scores by 45.6±18.1%, the Lequesne index from 9.0 [6.0; 13.0] to 5.0 [3.0; 9.0]; less than half (45.2%) of the patients still needed for NSAIDs. 82.2% of patients were satisfied or completely satisfied with treatment results; 89.6% reported good treatment tolerance.
Adverse events (apparently associated with NSAID use) were recorded in 2.2% of cases. There were no serious complications that required CS + GS treatment discontinuation or hospitalization.

Conclusion. The findings have indicated that Artroflex® used to support joint health is an effective agent that controls OA symptoms and has a good safety level.

About the Authors

A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522, Russia;


Yu. V. Barysheva
Regional Clinical Hospital
Russian Federation
7, Yakovlevskaya St., Yaroslavl 150062, Russia;


Ya. V. Belokon
Clinical Diagnostic Center, Tula Regional Clinical Hospital
Russian Federation
58, F. Engels St., Tula 300035, Russia;


T. Yu. Bolshakova
I.S. Berzon Krasnoyarsk Interdistrict Clinical Hospital Twenty
Russian Federation
12, Instrumentalnaya St., Krasnoyarsk 660123, Russia;


Yu. Yu. Grabovetskaya
Regional Clinical Hospital of the Kaliningrad Region
Russian Federation
74 Klinicheskaya St., Build. 1, Kaliningrad 236016, Russia;


E. A. Dolzhenkova
Regional Clinical Hospital
Russian Federation
3a, Internatsionalnaya St., Ryazan 390039, Russia;


L. N. Eliseeva
Kuban State Medical University, Ministry of Health of Russia
Russian Federation
4, M. Sedin St., Krasnodar 350063, Russia;


O. B. Ershova
Kursk Regional Clinical Hospital, Health Committee of the Kursk Region
Russian Federation
45a, Sumskaya St., Kursk 305007, Russia;


E. V. Zonova
Novosibirsk RZhD-Meditsina Clinical Hospital
Russian Federation
2a, Vladimirsky Spusk, Novosibirsk 630003, Russia;


I. Yu. Chernova
Novosibirsk RZhD-Meditsina Clinical Hospital
Russian Federation
2a, Vladimirsky Spusk, Novosibirsk 630003, Russia;


A. O. Isakanova
City Clinical Hospital One
Russian Federation
16, Vorovsky St., Build. 2, Chelyabinsk 454092, Russia;


M. N. Kirpikova
ArtraMed Diagnostic and Treatment Center
Russian Federation
27, Baturin St., Ivanovo 153037, Russia;


V. T. Komarov
N.N. Burdenko Penza Regional Clinical Hospital
Russian Federation
28, Lermontov St., Penza 440026, Russia;


E. V. Kryukova
Vologda Regional Clinical Hospital
Russian Federation
17, Lechebnaya St., Vologda 160002, Russia;


A. I. Kulikov
Regional Clinical Hospital Two
Russian Federation
33, First Cavalry Army St., Rostov-on-Don 344023, Russia;


D. I. Lakhin
Lipetsk Regional Clinical Hospital
Russian Federation
6A, Moskovskaya St., Lipetsk 398055, Russia;


L. A. Levasheva
Vladivostok Clinical Hospital Two
Russian Federation
57, Russkaya St., Vladivostok 690105, Russia;


L. V. Masneva
Saint Joasaph Belgorod Regional Clinical Hospital
Russian Federation
8/9, Nekrasov St., Belgorod 308007, Russia;


L. V. Menshikova
Irkutsk State Medical Academy of Postgraduate Education, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
100, Yubileinyi Microdistrict, Irkutsk 664049, Russia;


Yu. V. Mishina
Voronezh Regional Clinical Hospital One
Russian Federation
151, Moskovsky Prospect, Voronezh 394066, Russia;


S. V. Norina
City Clinical Polyclinic Three
Russian Federation
34, Dikopoltsev St., Khabarovsk 680000, Russia;


Yu. N. Pashkovsky
Vladimir City Hospital Six
Russian Federation
18, Institutskiy Small Town St., Vladimir 600901, Russia;


A. V. Petrov
S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University
Russian Federation
5/7, Lenin Boulevard, Simferopol 295051, Russia;


A. G. Rusanov
Saratov City Clinical Hospital Nine
Russian Federation
43B, Bolshaya Gornaya St., Saratov 410031, Russia;


A. V. Sarapulova
OOO «Angio Line» Medical Center
Russian Federation
56, Tchaikovsky St., Yekaterinburg 620142, Russia;


K. A. Svodtseva
Clinical Diagnostic Center, Tula Regional Clinical Hospital
Russian Federation
58, F. Engels St., Tula 300035, Russia;


O. V. Semagina
V.D. Seredavin Samara Regional Clinical Hospital
Russian Federation
159, Tashkentskaya St., Samara 443095, Russia;


A. N. Sudakova
Clinical Cardiology Dispensary
Russian Federation
41, Lermontov St., Omsk 644024, Russia;


S. N. Tkachenko
Consultative and Diagnostic Department, City Clinical Hospital Fifty-Two, Moscow Healthcare Department
Russian Federation
3, Pekhotnaya St., Build. 16, Moscow 123182, Russia;


M. M. Toporkov
S.M. Kirov Military Medical Academy
Russian Federation
6, Academician Lebedev St., Saint Petersburg 194044, Russia;


S. K. Tutelyan
Research Institute of Traumatology and Orthopedics, V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia
Russian Federation
148, Chernyshevsky St., Saratov 410002, Russia;


G. R. Fadienko
Regional Clinical Hospital One
Russian Federation
55, Kotovsky St., Tyumen 625023, Russia;


O. S. Filonenko
City Clinical Hospital Five
Russian Federation
9, Meditsinskaya St., Ryazan 390042, Russia;


O. P. Fomina
Amur Regional Clinical Hospital
Russian Federation
26, Voronkov St., Blagoveshchensk 675028, Russia;


A. S. Chernov
Volgograd State Medical University, Ministry of Health of Russia; City Clinical Emergency Hospital Twenty-Five
Russian Federation
1, Pavshikh Bortsov St, Volgograd 400131, Russia;
74, Zemlyachka St., Volgograd 400138, Russia


References

1. Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):9-21. (In Russ.) doi: 10.14412/1996-7012-2019-2-9-21

2. Grä ssel S, Muschter D. Recent advances in the treatment of osteoarthritis. F1000Res. 2020 May 4;9:F1000 Faculty Rev-325. doi: 10.12688/f1000research.22115.1.eCollection 2020.

3. Driban JB, Harkey MS, Barbe MF, et al. Risk factors and the natural history of accelerated knee osteoarthritis: a narrative review. BMC Musculoskelet Disord. 2020 May 29; 21(1):332. doi: 10.1186/s12891-020-03367-2.

4. Balabanova RM, Dubinina TV, Demina AB, Krichevskaya OA. Incidence of diseases of the musculoskeletal system in the Russian Federation for 2015-2016. Nauchno-prakticheskaya revmatologiya. 2018;56(1):15-21. (In Russ.)

5. Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Al'manakh klinicheskoi meditsiny. 2018;46(1):32-9. (In Russ.)

6. Cleveland RJ, Nelson AE, Callahan LF. Knee and hip osteoarthritis as predictors of premature death: a review of the evidence. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):24-30. Epub 2019 Oct 14.

7. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology Moscow: GEOTAR-Media; 2017. 446 p.

8. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Jul 3. pii: S1063-4584(19)31116-1. doi: 10.1016/j.joca.2019.06.011.

9. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020 Feb;72(2):220-33. doi: 10.1002/art.41142. Epub 2020 Jan 6.

10. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3): 337-50. doi: 10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.

11. Bruyere O, Cooper C, Al-Daghri NM, et al. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2018 Feb;30(2):111-17. doi: 10.1007/s40520-017-0861-1. Epub 2017 Nov 24.

12. Alekseeva LI. Delayed-action drugs in the treatment of osteoarthritis. Osteoporoz i osteopatii. 2012;(1):29-32. (In Russ.)

13. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014 Jul;78(3): 184-7. doi: 10.1016/j.maturitas.2014.04.015. Epub 2014 May 1.

14. Du Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacol Ther. 2014 Jun;142(3):362-74. doi: 10.1016/j.pharmthera.2014.01.002. Epub 2014 Jan 21.

15. Chichasova NV. Clinical rationale for the use of various teraflex formulations in osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2010;4(4):59-64. (In Russ.) doi: 10.14412/1996-7012-2010-639

16. DiNubile N. Glucosamine and Chondroitin Sulfate: What Has Been Learned Since the Glucosamine/chondroitin Arthritis Intervention Trial. Orthopedics. 2018 Jul 1; 41(4):200-07. doi: 10.3928/01477447-20180511-06. Epub 2018 May 18.

17. Lomonte ABV, Mendonca JA, de Castro Brandao G, Castro ML. Multicenter, randomized, double-blind clinical trial to evaluate efficacy and safety of combined glucosamine sulfate and chondroitin sulfate capsules for treating knee osteoarthritis. Adv Rheumatol. 2018 Dec 5;58(1):41. doi: 10.1186/s42358-018-0041-9.

18. Provenza JR, Shinjo SK, Silva JM, et al. Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis. Clin Rheumatol. 2015 Aug;34(8):1455-62. doi: 10.1007/s10067-014-2757-1. Epub 2014 Aug 3.

19. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23; 354(8):795-808. doi: 10.1056/NEJMoa052771.

20. Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016 Jan;75(1):37-44. doi: 10.1136/annrheumdis-2014-206792. Epub 2015 Jan 14.

21. Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015 May;74(5):851-8. doi: 10.1136/annrheumdis-2013-203954. Epub 2014 Jan 6.

22. Zhu X, Sang L, Wu D, Rong J, Jiang L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018 Jul 6;13(1):170. doi: 10.1186/s13018-018-0871-5.

23. Alekseeva LI. Combined drugs in the treatment of osteoarthritis. The effectiveness of teraflex. Meditsinskii Sovet. 2013;(4):100-5. (In Russ.)

24. Alekseeva LI, Sharapova EP. Use of Arthra MSM Forte and Arthra for osteoarthritis and back pain. Meditsinskii Sovet. 2017;(10): 96-101. (In Russ.)

25. Badokin VV. Synergistic and additive effects of chondroitin sulfate and glucosamine in the stimulation of cartilage in osteoarthritis. Effektivnaya farmakoterapiya, 2013;(38): 68-75. (In Russ.)

26. Rebrov AP, Romanova IA, Gaidukova IZ. Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(2): 37-42. (In Russ.) doi: 10.14412/1996-7012-2016-2-37-42

27. Karateev AE, Lila AM. Russian experience with injectable chondroitin sulfate and glucosamine sulfate: a review of clinical trials. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(1):33-40. (In Russ.) doi: 10.14412/1996-7012-2018-1-33-40

28. Dydykina IS, Kovalenko PS, Kovalenko AA. Many years of experience in using a combination of glucosamine and chondroitin in clinical practice. Meditsinskii sovet. 2020;(8): 113-9. (In Russ.)


Review

For citations:


Karateev AE, Barysheva YV, Belokon YV, Bolshakova TY, Grabovetskaya YY, Dolzhenkova EA, Eliseeva LN, Ershova OB, Zonova EV, Chernova IY, Isakanova AO, Kirpikova MN, Komarov VT, Kryukova EV, Kulikov AI, Lakhin DI, Levasheva LA, Masneva LV, Menshikova LV, Mishina YV, Norina SV, Pashkovsky YN, Petrov AV, Rusanov AG, Sarapulova AV, Svodtseva KA, Semagina OV, Sudakova AN, Tkachenko SN, Toporkov MM, Tutelyan SK, Fadienko GR, Filonenko OS, Fomina OP, Chernov AS. Evaluation of the efficacy and safety of a combination of chondroitin sulfate and glucosamine sulfate for knee and hip osteoarthritis in real clinical practice. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(4):82-90. (In Russ.) https://doi.org/10.14412/1996-7012-2020-4-82-90

Views: 1439


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)